Contents 3 min read

Claim and source comparison

Compared the Auteri 1992, McLean 1991 and Pavlík 1987 abstracts and the FDA letter. Open follow-up and pharmacokinetics were not presented as clinical efficacy or a comprehensive safety review; no independent medical review is established.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human pharmacokinetic study

Auteri et al. (1992) studied solution and tablet forms of 600 mg pramiracetam in 11 fasting volunteers. Plasma half-life varied between subjects from 2 to 8 hours; the study was not a fatty-meal comparison.

This small pharmacokinetic experiment does not establish a fixed 5–7-hour value, optimal meal, personal timing or cognitive-treatment dose. The absorption rates of solution and tablet do not establish clinical benefit or superiority to other racetams.

Source 3 · Abstract read

Human randomized controlled trial

McLean et al. (1991) reported improvement, particularly in delayed recall, in a double-blind placebo comparison in males with cognitive problems following brain injury or anoxia. The studied product was pramiracetam sulfate, 400 mg three times daily, followed by 18 months of open treatment and one month of post-discontinuation follow-up.

The abstract does not provide the controlled phase’s sample size; PubMed classifies it as randomized. The open 18-month follow-up was not placebo-controlled. These findings cannot be transferred to healthy users, personal doses or general long-term safety.

Source 4 · Abstract read

Animal study

Pavlík et al. (1987) reported increased hippocampal high-affinity choline uptake (HACU) after 6 days of pramiracetam or oxiracetam in male rats; striatal dopamine and HVA were unchanged.

This is an animal biochemical finding; it does not demonstrate human memory enhancement, choline deficiency or a need for choline supplementation. HACU measurement is not evidence of clinical efficacy or safe drug combinations.

Source 5 · Abstract read

Regulatory scientific assessment

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.

Source 6 · Official summary read

Our evidence and source methodology

pramiracetam: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Pramiracetam?

Pramiracetam is a synthetic racetam with investigated cholinergic mechanisms. Small, older clinical trials do not establish general cognitive enhancement or superiority to other racetams.

Mechanism of Effect

Pavlík et al. (1987) reported increased hippocampal high-affinity choline uptake (HACU) after 6 days of pramiracetam or oxiracetam in male rats; striatal dopamine and HVA were unchanged.

This is an animal biochemical finding; it does not demonstrate human memory enhancement, choline deficiency or a need for choline supplementation. HACU measurement is not evidence of clinical efficacy or safe drug combinations.

Clinical Evidence

McLean et al. (1991) reported improvement, particularly in delayed recall, in a double-blind placebo comparison in males with cognitive problems following brain injury or anoxia. The studied product was pramiracetam sulfate, 400 mg three times daily, followed by 18 months of open treatment and one month of post-discontinuation follow-up.

The abstract does not provide the controlled phase’s sample size; PubMed classifies it as randomized. The open 18-month follow-up was not placebo-controlled. These findings cannot be transferred to healthy users, personal doses or general long-term safety.

Dose information and research limits

Auteri et al. (1992) studied solution and tablet forms of 600 mg pramiracetam in 11 fasting volunteers. Plasma half-life varied between subjects from 2 to 8 hours; the study was not a fatty-meal comparison.

This small pharmacokinetic experiment does not establish a fixed 5–7-hour value, optimal meal, personal timing or cognitive-treatment dose. The absorption rates of solution and tablet do not establish clinical benefit or superiority to other racetams.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

The accessed pharmacokinetic and limited clinical data do not establish long-term safe use or the safety of drug combinations. Added choline has not been shown to prevent adverse effects; absence of an interaction record is not evidence of safety.

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.

Sources

  1. Malykh, A.G., Sadaie, M.R. (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. PubMed · PMID 20166767
  2. Gouliaev, A.H., Senning, A. (1994). Piracetam and other structurally related nootropics. Brain Research Reviews, 19(2), 180–222. PubMed · PMID 8061686
  3. Auteri A, et al. (1992). Pharmacokinetics of pramiracetam in healthy volunteers after oral administration. International Journal of Clinical Pharmacology Research, 12(3), 129–32. PubMed · PMID 1473879
  4. McLean A Jr, et al. (1991). Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia. Brain Injury, 5(4), 375–80. https://doi.org/10.3109/02699059109008110 PubMed · PMID 1786500
  5. Pavlík A, Benesová O, Dlohozková N. (1987). Effects of nootropic drugs on brain cholinergic and dopaminergic transmission. Activitas Nervosa Superior, 29(1), 62–65. PubMed · PMID 3035858
  6. US Food and Drug Administration. (2019). Warning Letter: Peak Nootropics LLC aka Advanced Nootropics. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 US Food and Drug Administration

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions